ES2140402T3 - Inhibidor nuclear i-92 y su uso para la produccion de un medicamento. - Google Patents

Inhibidor nuclear i-92 y su uso para la produccion de un medicamento.

Info

Publication number
ES2140402T3
ES2140402T3 ES92115730T ES92115730T ES2140402T3 ES 2140402 T3 ES2140402 T3 ES 2140402T3 ES 92115730 T ES92115730 T ES 92115730T ES 92115730 T ES92115730 T ES 92115730T ES 2140402 T3 ES2140402 T3 ES 2140402T3
Authority
ES
Spain
Prior art keywords
production
nuclear inhibitor
medicinal product
nuclear
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92115730T
Other languages
English (en)
Inventor
Jurgen Weitz
Michael Stohr
Inge Napierski
Hans-Dieter Max Dellbruc Royer
Marijana Kopun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Application granted granted Critical
Publication of ES2140402T3 publication Critical patent/ES2140402T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN INHIBIDOR NUCLEAR QUE INHIBE ESPECIFICAMENTE LA ACTIVIDAD DE LAS PROTEINAS DE UNION MEJORADORAS DEL DNA DE SECUENCIA ESPECIFICA DEL VIRUS DEL PAPILOMA HUMANO (HPV), ASIMISMO SE REFIERE AL USO DEL INHIBIDOR NUCLEAR PARA LA PRODUCCION DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CANCER CERVICAL HUMANO.
ES92115730T 1991-10-09 1992-09-15 Inhibidor nuclear i-92 y su uso para la produccion de un medicamento. Expired - Lifetime ES2140402T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91117184 1991-10-09

Publications (1)

Publication Number Publication Date
ES2140402T3 true ES2140402T3 (es) 2000-03-01

Family

ID=8207249

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92115730T Expired - Lifetime ES2140402T3 (es) 1991-10-09 1992-09-15 Inhibidor nuclear i-92 y su uso para la produccion de un medicamento.

Country Status (8)

Country Link
US (1) US6045831A (es)
EP (1) EP0536563B1 (es)
JP (1) JPH06245787A (es)
AT (1) ATE188706T1 (es)
AU (1) AU669129B2 (es)
CA (1) CA2080182C (es)
DE (1) DE69230550T2 (es)
ES (1) ES2140402T3 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0744808B2 (ja) * 1987-02-19 1995-05-15 ▲えな▼吉 早坂 磁気制御同性磁極誘導発電機
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease

Also Published As

Publication number Publication date
AU2627892A (en) 1993-04-22
AU669129B2 (en) 1996-05-30
JPH06245787A (ja) 1994-09-06
EP0536563B1 (en) 2000-01-12
US6045831A (en) 2000-04-04
CA2080182C (en) 2002-12-10
EP0536563A1 (en) 1993-04-14
ATE188706T1 (de) 2000-01-15
CA2080182A1 (en) 1993-04-10
DE69230550D1 (de) 2000-02-17
DE69230550T2 (de) 2000-05-25

Similar Documents

Publication Publication Date Title
ES2188586T3 (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura.
ES2136088T3 (es) Compuestos inmunogenos con efecto principalmente anti-citoquina, procedimiento de preparacion, composiciones farmaceuticas y kits que los contienen.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
DE60107203D1 (de) Herpes-virusstämme für die gentherapie
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
ES2194468T3 (es) Uso de derivados del bisindol indigoide para la fabricacion de un medicamento para inhibir quinasas dependientes de ciclinas.
MX9702272A (es) Inhibicion del crecimiento del cabello.
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
FI963070A0 (fi) Klooripyrimidiinivälituotteita
ES8703490A1 (es) Un procedimiento para producir un polipeptido que tiene o contiene un polipeptido de factor de necrosis de tumor humano
ES2075011T3 (es) Uso de sales del acido gamma-hidroxibutirico para preparar composiciones farmaceuticas para uso en el tratamiento del alcoholismo, y las composiciones obtenidas.
ES2080307T3 (es) Composiciones farmaceuticas.
ES2192680T3 (es) Nuevos derivados de vitamina d con sustituyentes carbo- o heterociclicos en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
BG103219A (bg) Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
SE9701161D0 (sv) New use I
ES2145818T3 (es) Utilizacion de la (s)-(-)-alfa-etil-2-oxo-1-pirrolidin-acetamida para la preparacion de medicamentos destinados al tratamiento de la ansiedad.
ES2038593T3 (es) Un procedimiento para preparar manosil-aglicona del antibiotico a 40926.
ES2145360T3 (es) Sales cristalinas y estables de acido tetrahidrofolico.
ES2037808T3 (es) Procedimiento para la obtencion de medicamentos para la profilaxis y terapia de enfermedades producidas por retrovirus.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
ES2071143T3 (es) Factores b1, b2, c1, c2, d1, d2, e y t del antibiotico ge 2270.
DK0681473T3 (da) Præparater, der indeholder tandospiron eller dets analoger
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 536563

Country of ref document: ES